Microbiology Quiz: Nucleic Acid Synthesis Inhibitors
20 questions · exam conditions
0:00
Nucleic Acid Synthesis InhibitorsQuestion 1 of 20

Both rifampin and fluoroquinolones interfere with processes involving the bacterial chromosome, but their effects are distinct. Which of the following experimental observations would uniquely indicate treatment with rifampin but NOT a fluoroquinolone?

A rapid decrease in the incorporation of radiolabeled thymidine into macromolecules.
Accumulation of double-strand breaks in the bacterial chromosome upon cell division.
A rapid decrease in the incorporation of radiolabeled uridine into macromolecules.
Failure to decatenate intertwined daughter chromosomes after replication is complete.
← Back to quizzes

Microbiology Quiz

Microbiology Quiz: Nucleic Acid Synthesis Inhibitors

Practice Nucleic Acid Synthesis Inhibitors in Microbiology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Nucleic Acid Synthesis Inhibitors, giving you a quick way to practice the rules, question types, and explanations that matter most for Microbiology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

Both rifampin and fluoroquinolones interfere with processes involving the bacterial chromosome, but their effects are distinct. Which of the following experimental observations would uniquely indicate treatment with rifampin but NOT a fluoroquinolone?

  1. A rapid decrease in the incorporation of radiolabeled thymidine into macromolecules.
  2. Accumulation of double-strand breaks in the bacterial chromosome upon cell division.
  3. A rapid decrease in the incorporation of radiolabeled uridine into macromolecules. (correct answer)
  4. Failure to decatenate intertwined daughter chromosomes after replication is complete.
Explanation: Radiolabeled thymidine is used to measure DNA synthesis. Fluoroquinolones inhibit DNA replication, so they would cause a decrease in thymidine incorporation. Radiolabeled uridine is used to measure RNA synthesis. Rifampin inhibits RNA polymerase, so it would cause a rapid decrease in uridine incorporation. The other options describe effects of fluoroquinolones (double-strand breaks and decatenation failure). Therefore, a rapid drop in uridine incorporation is the unique indicator of rifampin's action.

Question 2

A researcher is developing a new fluoroquinolone antibiotic. Initial studies show it has potent activity against Streptococcus pneumoniae but significantly weaker activity against Pseudomonas aeruginosa. This differential activity most likely reflects a higher binding affinity of the new drug for which target?

  1. DNA gyrase over topoisomerase IV.
  2. Topoisomerase IV over DNA gyrase. (correct answer)
  3. DNA-dependent RNA polymerase over DNA polymerase III.
  4. Dihydrofolate reductase over dihydropteroate synthase.
Explanation: Fluoroquinolones have two primary targets: DNA gyrase and topoisomerase IV. In most Gram-positive bacteria, such as Streptococcus pneumoniae, the primary target is topoisomerase IV. In most Gram-negative bacteria, like Pseudomonas aeruginosa, the primary target is DNA gyrase. Therefore, a drug with high potency against a Gram-positive and weaker potency against a Gram-negative likely has a higher affinity for topoisomerase IV.

Question 3

An in vitro experiment is set up with purified bacterial DNA gyrase, supercoiled plasmid DNA, and ATP. The reaction normally results in the introduction of negative supercoils. If levofloxacin is added, the reaction is inhibited. If the experiment is repeated with rifampin instead of levofloxacin, what would be the expected outcome?

  1. The reaction would be inhibited because rifampin also targets DNA gyrase.
  2. The reaction rate would increase due to allosteric activation of DNA gyrase by rifampin.
  3. The reaction would produce fragmented plasmid DNA due to rifampin-induced strand breaks.
  4. The reaction would proceed normally, producing negatively supercoiled plasmid DNA. (correct answer)
Explanation: When you encounter questions about antibiotic mechanisms, focus on understanding each drug's specific molecular target. This question tests whether you can distinguish between different classes of antibiotics based on their sites of action. DNA gyrase is a bacterial topoisomerase that relieves supercoiling tension during DNA replication by introducing negative supercoils. The experiment demonstrates this normal function using purified components. Levofloxacin, a fluoroquinolone antibiotic, specifically inhibits DNA gyrase by binding to the gyrase-DNA complex and preventing the enzyme from completing its catalytic cycle. Rifampin, however, targets an entirely different enzyme: bacterial RNA polymerase. It binds to the β-subunit of RNA polymerase and blocks the exit path for nascent RNA transcripts, effectively shutting down transcription. Since rifampin doesn't interact with DNA gyrase, it won't interfere with the supercoiling reaction in this in vitro system. The reaction would proceed normally, producing negatively supercoiled plasmid DNA. Answer A is incorrect because rifampin targets RNA polymerase, not DNA gyrase. Answer B is wrong because rifampin doesn't interact with DNA gyrase at all, so it cannot cause allosteric activation. Answer C is incorrect because rifampin doesn't cause DNA strand breaks—it's not a nuclease and doesn't damage DNA structure. For microbiology exams, memorize the major antibiotic classes and their specific targets: fluoroquinolones hit DNA gyrase/topoisomerase IV, rifamycins target RNA polymerase, β-lactams inhibit cell wall synthesis, and aminoglycosides affect ribosomal protein synthesis. Knowing these mechanisms prevents confusion between similar-sounding drugs.

Question 4

Sulfonamides exert their antibacterial effect by acting as competitive inhibitors of dihydropteroate synthase. This inhibition is possible because sulfonamides are structural analogs of which essential bacterial metabolite?

  1. Dihydrofolic acid (DHF).
  2. Tetrahydrofolic acid (THF).
  3. Para-aminobenzoic acid (PABA). (correct answer)
  4. Guanosine triphosphate (GTP).
Explanation: Competitive inhibitors often function by mimicking the structure of the enzyme's natural substrate. Dihydropteroate synthase catalyzes the reaction between dihydropterin pyrophosphate and para-aminobenzoic acid (PABA) to form dihydropteroic acid. Sulfonamides are structurally very similar to PABA, allowing them to bind to the active site of the enzyme and compete with the natural substrate, thus inhibiting the folate synthesis pathway.

Question 5

Metronidazole is highly effective against Clostridium difficile, an obligate anaerobe, but has no activity against Staphylococcus aureus under aerobic conditions. This selective toxicity is primarily because:

  1. Staphylococcus aureus possesses an efficient drug efflux pump that is absent in Clostridium difficile.
  2. The drug requires reductive activation by low-redox-potential electron transport proteins unique to anaerobic metabolism. (correct answer)
  3. The ribosomal subunits of Staphylococcus aureus have a different structure than those of Clostridium difficile.
  4. The DNA topoisomerases in aerobic bacteria are structurally different and not susceptible to the drug's action.
Explanation: Metronidazole is a prodrug that is inactive until its nitro group is reduced. This reduction is carried out by proteins like ferredoxin or flavodoxin, which have a sufficiently low redox potential and are characteristic of anaerobic metabolic pathways. Aerobic organisms lack these specific low-potential electron transport systems, so the drug is not activated and remains non-toxic.

Question 6

The principle of selective toxicity for fluoroquinolones relies on structural differences between prokaryotic and eukaryotic topoisomerases. How does this basis for selectivity differ from that of the rifamycin class of antibiotics?

  1. It does not differ; rifamycins also exploit structural differences between prokaryotic and eukaryotic RNA polymerases. (correct answer)
  2. Rifamycins are selective because eukaryotic cells are impermeable to the drug, whereas quinolones are selective at the target level.
  3. Rifamycins are selective because eukaryotes use multiple insensitive RNA polymerases, whereas quinolones target a single bacterial enzyme.
  4. Fluoroquinolones are selective because they target an enzyme unique to bacteria, whereas rifamycins target a universally conserved enzyme.
Explanation: The basis for selective toxicity is fundamentally the same for both classes. Both fluoroquinolones and rifamycins target enzymes (topoisomerases and RNA polymerase, respectively) that have essential functional homologs in eukaryotic cells. Their selective toxicity arises from significant structural differences between the prokaryotic and eukaryotic versions of these enzymes, which allows the drugs to bind with high affinity to the bacterial target while having very low affinity for the host's counterpart.

Question 7

A microbiologist observes that when a novel antibiotic is added to a logarithmically growing culture of E. coli, the cells elongate and form long filaments. Staining with a DNA-binding dye reveals that the nucleoids are improperly segregated and appear fragmented. This phenotype is most characteristic of an inhibitor of:

  1. Peptidoglycan synthesis.
  2. The 50S ribosomal subunit.
  3. DNA gyrase and topoisomerase IV. (correct answer)
  4. Folic acid synthesis.
Explanation: Inhibition of DNA gyrase and topoisomerase IV by agents like quinolones causes DNA replication to stall and leads to DNA damage. This damage induces the bacterial SOS response, which inhibits cell division (septum formation) but allows cell growth to continue, resulting in filamentation. Furthermore, the failure of topoisomerase IV to decatenate (unlink) replicated chromosomes prevents proper nucleoid segregation. This combination of filamentation and aberrant nucleoid morphology is a hallmark of this class of inhibitors.

Question 8

A strain of Mycobacterium tuberculosis is isolated that shows resistance to rifampin. DNA sequencing reveals a point mutation in the rpoB gene. This mutation most likely interferes with which specific molecular interaction?

  1. The drug's ability to bind to the beta subunit of DNA-dependent RNA polymerase. (correct answer)
  2. The ability of DNA gyrase to introduce negative supercoils ahead of the replication fork.
  3. The catalytic activity of dihydrofolate reductase, preventing the synthesis of tetrahydrofolate.
  4. The formation of the initial phosphodiester bond by RNA polymerase during transcription elongation.
Explanation: The rpoB gene encodes the beta subunit of bacterial RNA polymerase. This subunit forms part of the active site and is the direct binding target for rifampin. Mutations in rpoB alter the binding pocket, preventing the drug from inhibiting the enzyme, which is the most common mechanism of rifampin resistance.

Question 9

Rifampin is a potent inhibitor of bacterial transcription. Its mechanism is best described as sterically blocking the path of the elongating RNA transcript. At which point does this blockade effectively halt transcription?

  1. It prevents the binding of the RNA polymerase holoenzyme to the promoter DNA sequence.
  2. It destabilizes the open promoter complex, causing RNA polymerase to dissociate before initiating synthesis.
  3. It allows for synthesis of a full-length mRNA but prevents release of the transcript from the polymerase.
  4. It allows transcription initiation but prevents the transcript from extending beyond two or three nucleotides. (correct answer)
Explanation: When you encounter questions about antibiotic mechanisms, focus on understanding exactly where in the cellular process the drug intervenes. Rifampin specifically targets bacterial RNA polymerase, but the key is understanding the precise timing of its inhibitory effect. Rifampin works by binding to the β-subunit of bacterial RNA polymerase and creating a physical blockade in the RNA exit channel. This mechanism allows the polymerase to bind normally to the promoter and begin transcription initiation, but the growing RNA transcript quickly encounters the rifampin-created obstruction. The result is abortive transcription - the polymerase can only synthesize very short RNA fragments of 2-3 nucleotides before the transcript collides with the drug and transcription terminates. This makes D correct. A is incorrect because rifampin doesn't prevent initial polymerase binding to DNA - the holoenzyme can still recognize and bind promoters normally. B is wrong because the open promoter complex forms successfully; rifampin doesn't interfere with DNA melting or early promoter interactions. C describes a completely different mechanism where full-length transcripts are made but can't be released - this isn't how rifampin works at all. Remember that rifampin's selectivity comes from structural differences between bacterial and eukaryotic RNA polymerases. For microbiology exams, always consider both the molecular target of an antibiotic and the precise step in the process where inhibition occurs - many drugs affect the same pathway but at different points.

Question 10

Metronidazole is highly effective against Clostridium difficile, an obligate anaerobe, but has no activity against Staphylococcus aureus under aerobic conditions. This selective toxicity is primarily because:

  1. Staphylococcus aureus possesses an efficient drug efflux pump that is absent in Clostridium difficile.
  2. The drug requires reductive activation by low-redox-potential electron transport proteins unique to anaerobic metabolism. (correct answer)
  3. The ribosomal subunits of Staphylococcus aureus have a different structure than those of Clostridium difficile.
  4. The DNA topoisomerases in aerobic bacteria are structurally different and not susceptible to the drug's action.
Explanation: Metronidazole is a prodrug that is inactive until its nitro group is reduced. This reduction is carried out by proteins like ferredoxin or flavodoxin, which have a sufficiently low redox potential and are characteristic of anaerobic metabolic pathways. Aerobic organisms lack these specific low-potential electron transport systems, so the drug is not activated and remains non-toxic.

Question 11

A strain of Mycobacterium tuberculosis is isolated that shows resistance to rifampin. DNA sequencing reveals a point mutation in the rpoB gene. This mutation most likely interferes with which specific molecular interaction?

  1. The drug's ability to bind to the beta subunit of DNA-dependent RNA polymerase. (correct answer)
  2. The ability of DNA gyrase to introduce negative supercoils ahead of the replication fork.
  3. The catalytic activity of dihydrofolate reductase, preventing the synthesis of tetrahydrofolate.
  4. The formation of the initial phosphodiester bond by RNA polymerase during transcription elongation.
Explanation: The rpoB gene encodes the beta subunit of bacterial RNA polymerase. This subunit forms part of the active site and is the direct binding target for rifampin. Mutations in rpoB alter the binding pocket, preventing the drug from inhibiting the enzyme, which is the most common mechanism of rifampin resistance.

Question 12

A researcher is developing a new fluoroquinolone antibiotic. Initial studies show it has potent activity against Streptococcus pneumoniae but significantly weaker activity against Pseudomonas aeruginosa. This differential activity most likely reflects a higher binding affinity of the new drug for which target?

  1. DNA gyrase over topoisomerase IV.
  2. Topoisomerase IV over DNA gyrase. (correct answer)
  3. DNA-dependent RNA polymerase over DNA polymerase III.
  4. Dihydrofolate reductase over dihydropteroate synthase.
Explanation: Fluoroquinolones have two primary targets: DNA gyrase and topoisomerase IV. In most Gram-positive bacteria, such as Streptococcus pneumoniae, the primary target is topoisomerase IV. In most Gram-negative bacteria, like Pseudomonas aeruginosa, the primary target is DNA gyrase. Therefore, a drug with high potency against a Gram-positive and weaker potency against a Gram-negative likely has a higher affinity for topoisomerase IV.

Question 13

Rifampin is a potent inhibitor of bacterial transcription. Its mechanism is best described as sterically blocking the path of the elongating RNA transcript. At which point does this blockade effectively halt transcription?

  1. It prevents the binding of the RNA polymerase holoenzyme to the promoter DNA sequence.
  2. It destabilizes the open promoter complex, causing RNA polymerase to dissociate before initiating synthesis.
  3. It allows for synthesis of a full-length mRNA but prevents release of the transcript from the polymerase.
  4. It allows transcription initiation but prevents the transcript from extending beyond two or three nucleotides. (correct answer)
Explanation: When you encounter questions about antibiotic mechanisms, focus on understanding exactly where in the cellular process the drug intervenes. Rifampin specifically targets bacterial RNA polymerase, but the key is understanding the precise timing of its inhibitory effect. Rifampin works by binding to the β-subunit of bacterial RNA polymerase and creating a physical blockade in the RNA exit channel. This mechanism allows the polymerase to bind normally to the promoter and begin transcription initiation, but the growing RNA transcript quickly encounters the rifampin-created obstruction. The result is abortive transcription - the polymerase can only synthesize very short RNA fragments of 2-3 nucleotides before the transcript collides with the drug and transcription terminates. This makes D correct. A is incorrect because rifampin doesn't prevent initial polymerase binding to DNA - the holoenzyme can still recognize and bind promoters normally. B is wrong because the open promoter complex forms successfully; rifampin doesn't interfere with DNA melting or early promoter interactions. C describes a completely different mechanism where full-length transcripts are made but can't be released - this isn't how rifampin works at all. Remember that rifampin's selectivity comes from structural differences between bacterial and eukaryotic RNA polymerases. For microbiology exams, always consider both the molecular target of an antibiotic and the precise step in the process where inhibition occurs - many drugs affect the same pathway but at different points.

Question 14

An in vitro experiment is set up with purified bacterial DNA gyrase, supercoiled plasmid DNA, and ATP. The reaction normally results in the introduction of negative supercoils. If levofloxacin is added, the reaction is inhibited. If the experiment is repeated with rifampin instead of levofloxacin, what would be the expected outcome?

  1. The reaction would be inhibited because rifampin also targets DNA gyrase.
  2. The reaction rate would increase due to allosteric activation of DNA gyrase by rifampin.
  3. The reaction would produce fragmented plasmid DNA due to rifampin-induced strand breaks.
  4. The reaction would proceed normally, producing negatively supercoiled plasmid DNA. (correct answer)
Explanation: When you encounter questions about antibiotic mechanisms, focus on understanding each drug's specific molecular target. This question tests whether you can distinguish between different classes of antibiotics based on their sites of action. DNA gyrase is a bacterial topoisomerase that relieves supercoiling tension during DNA replication by introducing negative supercoils. The experiment demonstrates this normal function using purified components. Levofloxacin, a fluoroquinolone antibiotic, specifically inhibits DNA gyrase by binding to the gyrase-DNA complex and preventing the enzyme from completing its catalytic cycle. Rifampin, however, targets an entirely different enzyme: bacterial RNA polymerase. It binds to the β-subunit of RNA polymerase and blocks the exit path for nascent RNA transcripts, effectively shutting down transcription. Since rifampin doesn't interact with DNA gyrase, it won't interfere with the supercoiling reaction in this in vitro system. The reaction would proceed normally, producing negatively supercoiled plasmid DNA. Answer A is incorrect because rifampin targets RNA polymerase, not DNA gyrase. Answer B is wrong because rifampin doesn't interact with DNA gyrase at all, so it cannot cause allosteric activation. Answer C is incorrect because rifampin doesn't cause DNA strand breaks—it's not a nuclease and doesn't damage DNA structure. For microbiology exams, memorize the major antibiotic classes and their specific targets: fluoroquinolones hit DNA gyrase/topoisomerase IV, rifamycins target RNA polymerase, β-lactams inhibit cell wall synthesis, and aminoglycosides affect ribosomal protein synthesis. Knowing these mechanisms prevents confusion between similar-sounding drugs.

Question 15

The action of quinolones on bacterial topoisomerases leads to the formation of stalled cleavage complexes, which are converted into lethal double-strand DNA breaks. This bactericidal effect is most pronounced under which cellular condition?

  1. During stationary phase when DNA replication is minimal.
  2. In anaerobic environments where DNA repair mechanisms are less efficient.
  3. During conditions of oxidative stress, which enhances drug binding to DNA.
  4. In actively dividing cells undergoing DNA replication. (correct answer)
Explanation: Questions about antibiotic mechanisms often test whether you understand how a drug's mechanism of action relates to when it's most effective during the bacterial life cycle. Quinolones work by inhibiting bacterial topoisomerases (DNA gyrase and topoisomerase IV), enzymes essential for relieving tension in DNA during replication and transcription. When quinolones bind to these enzymes, they form stable cleavage complexes that block the re-ligation of DNA strands. These stalled complexes then convert into lethal double-strand breaks as the replication machinery attempts to proceed. This bactericidal effect is most pronounced in actively dividing cells undergoing DNA replication (D) because that's precisely when topoisomerases are working hardest and when stalled replication forks cause the most damage. Option A is incorrect because stationary phase bacteria have minimal DNA replication, so there's less topoisomerase activity and fewer opportunities for quinolones to form lethal cleavage complexes. Option B misses the mark—while anaerobic conditions might affect some cellular processes, the key factor for quinolone effectiveness is DNA replication activity, not oxygen availability or repair efficiency. Option C incorrectly suggests that oxidative stress enhances drug binding to DNA, but quinolones target enzymes, not DNA directly, and their effectiveness depends on enzymatic activity rather than oxidative conditions. Remember: antibiotics that target DNA replication machinery (like quinolones) are most effective against rapidly dividing bacteria because that's when their target processes are most active.

Question 16

A clinical isolate of E. coli develops a mutation in the gyrA gene, conferring high-level resistance to ciprofloxacin. Which statement accurately predicts the susceptibility of this mutant strain to other antimicrobials?

  1. It will likely show cross-resistance to rifampin due to the close proximity of their targets on the chromosome.
  2. It will likely show increased susceptibility to sulfonamides as a compensatory mechanism.
  3. It will likely be resistant to metronidazole because both drugs ultimately cause DNA damage.
  4. It will likely remain susceptible to trimethoprim because folate synthesis is an independent metabolic pathway. (correct answer)
Explanation: When you encounter questions about antibiotic resistance mutations, focus on the specific mechanism of action for each drug and whether they share common targets or pathways. GyrA encodes DNA gyrase subunit A, the primary target of fluoroquinolones like ciprofloxacin. A mutation conferring high-level ciprofloxacin resistance affects this specific enzyme but doesn't directly impact other antimicrobial targets or pathways. Trimethoprim inhibits dihydrofolate reductase in the folate synthesis pathway, which is completely independent of DNA gyrase function. Since the gyrA mutation only affects DNA supercoiling machinery, it won't influence folate metabolism enzymes. Therefore, the mutant strain should remain susceptible to trimethoprim, making answer D correct. Here's why the other options are incorrect: A is wrong because rifampin targets RNA polymerase, not DNA gyrase, and chromosomal proximity doesn't determine cross-resistance—the mechanism of action does. B is incorrect because there's no compensatory mechanism that would increase sulfonamide susceptibility; if anything, resistance mutations rarely make bacteria more susceptible to unrelated drugs. C is misleading because while both ciprofloxacin and metronidazole can cause DNA damage, they work through entirely different mechanisms—metronidazole requires anaerobic reduction to form toxic metabolites, which is unrelated to DNA gyrase function. Remember: cross-resistance occurs when drugs share the same target or when resistance mechanisms (like efflux pumps) affect multiple drugs. Always identify each drug's specific target before predicting resistance patterns.

Question 17

A microbiologist observes that when a novel antibiotic is added to a logarithmically growing culture of E. coli, the cells elongate and form long filaments. Staining with a DNA-binding dye reveals that the nucleoids are improperly segregated and appear fragmented. This phenotype is most characteristic of an inhibitor of:

  1. Peptidoglycan synthesis.
  2. The 50S ribosomal subunit.
  3. DNA gyrase and topoisomerase IV. (correct answer)
  4. Folic acid synthesis.
Explanation: Inhibition of DNA gyrase and topoisomerase IV by agents like quinolones causes DNA replication to stall and leads to DNA damage. This damage induces the bacterial SOS response, which inhibits cell division (septum formation) but allows cell growth to continue, resulting in filamentation. Furthermore, the failure of topoisomerase IV to decatenate (unlink) replicated chromosomes prevents proper nucleoid segregation. This combination of filamentation and aberrant nucleoid morphology is a hallmark of this class of inhibitors.

Question 18

The principle of selective toxicity for fluoroquinolones relies on structural differences between prokaryotic and eukaryotic topoisomerases. How does this basis for selectivity differ from that of the rifamycin class of antibiotics?

  1. It does not differ; rifamycins also exploit structural differences between prokaryotic and eukaryotic RNA polymerases. (correct answer)
  2. Rifamycins are selective because eukaryotic cells are impermeable to the drug, whereas quinolones are selective at the target level.
  3. Rifamycins are selective because eukaryotes use multiple insensitive RNA polymerases, whereas quinolones target a single bacterial enzyme.
  4. Fluoroquinolones are selective because they target an enzyme unique to bacteria, whereas rifamycins target a universally conserved enzyme.
Explanation: The basis for selective toxicity is fundamentally the same for both classes. Both fluoroquinolones and rifamycins target enzymes (topoisomerases and RNA polymerase, respectively) that have essential functional homologs in eukaryotic cells. Their selective toxicity arises from significant structural differences between the prokaryotic and eukaryotic versions of these enzymes, which allows the drugs to bind with high affinity to the bacterial target while having very low affinity for the host's counterpart.

Question 19

Sulfonamides exert their antibacterial effect by acting as competitive inhibitors of dihydropteroate synthase. This inhibition is possible because sulfonamides are structural analogs of which essential bacterial metabolite?

  1. Dihydrofolic acid (DHF).
  2. Tetrahydrofolic acid (THF).
  3. Para-aminobenzoic acid (PABA). (correct answer)
  4. Guanosine triphosphate (GTP).
Explanation: Competitive inhibitors often function by mimicking the structure of the enzyme's natural substrate. Dihydropteroate synthase catalyzes the reaction between dihydropterin pyrophosphate and para-aminobenzoic acid (PABA) to form dihydropteroic acid. Sulfonamides are structurally very similar to PABA, allowing them to bind to the active site of the enzyme and compete with the natural substrate, thus inhibiting the folate synthesis pathway.

Question 20

A clinical isolate of E. coli develops a mutation in the gyrA gene, conferring high-level resistance to ciprofloxacin. Which statement accurately predicts the susceptibility of this mutant strain to other antimicrobials?

  1. It will likely show cross-resistance to rifampin due to the close proximity of their targets on the chromosome.
  2. It will likely show increased susceptibility to sulfonamides as a compensatory mechanism.
  3. It will likely be resistant to metronidazole because both drugs ultimately cause DNA damage.
  4. It will likely remain susceptible to trimethoprim because folate synthesis is an independent metabolic pathway. (correct answer)
Explanation: When you encounter questions about antibiotic resistance mutations, focus on the specific mechanism of action for each drug and whether they share common targets or pathways. GyrA encodes DNA gyrase subunit A, the primary target of fluoroquinolones like ciprofloxacin. A mutation conferring high-level ciprofloxacin resistance affects this specific enzyme but doesn't directly impact other antimicrobial targets or pathways. Trimethoprim inhibits dihydrofolate reductase in the folate synthesis pathway, which is completely independent of DNA gyrase function. Since the gyrA mutation only affects DNA supercoiling machinery, it won't influence folate metabolism enzymes. Therefore, the mutant strain should remain susceptible to trimethoprim, making answer D correct. Here's why the other options are incorrect: A is wrong because rifampin targets RNA polymerase, not DNA gyrase, and chromosomal proximity doesn't determine cross-resistance—the mechanism of action does. B is incorrect because there's no compensatory mechanism that would increase sulfonamide susceptibility; if anything, resistance mutations rarely make bacteria more susceptible to unrelated drugs. C is misleading because while both ciprofloxacin and metronidazole can cause DNA damage, they work through entirely different mechanisms—metronidazole requires anaerobic reduction to form toxic metabolites, which is unrelated to DNA gyrase function. Remember: cross-resistance occurs when drugs share the same target or when resistance mechanisms (like efflux pumps) affect multiple drugs. Always identify each drug's specific target before predicting resistance patterns.